Sialix is developing therapeutic antibodies targeting glycan alterations present in the majority of solid tumors — including colon, lung, ovarian, breast, prostate, and pancreatic cancer. Cancer cells mutate the glycans present on the cell surface to enable tissue invasion and metastases. Targeting glycans with antibodies offers the potential to provide patients with significant benefits in reducing tumor burden by both killing tumor cells and blocking metastatic behavior. In addition, glycan-targeted antibodies may serve as a highly cancer-specific targeted mechanism for antibody-drug conjugates (ADCs).
Sialix has developed a platform of technologies that enable the creation of highly specific, high affinity, therapeutic quality anti-glycan antibodies (SiaMabsTM). Sialix’s SiaMabTM platform enables rapid screening of candidate antibodies and mapping of binding epitopes. Sialix’s core technologies were licensed from the laboratory of Dr. Ajit Varki (UCSD), a world expert in glycobiology and sialic-acid biochemistry.